Create an Account
  1. Home
  2. Meetings
  3. General Ophthalmology

Challenges With Postoperative Posterior Segment Inflammation

Challenges With Postoperative Posterior Segment Inflammation
Media formats available:
Details
Presenters

  • Overview

    Research indicates that sustained-release implants may have better efficacy and fewer systemic side effects when treating posterior segment uveitis than other corticosteroid delivery options or alternative nonsteroidal treatments. To provide the best treatment possible for patients undergoing eye surgery, ophthalmologists must have a thorough understanding of all available options and their benefits and challenges. 

    This webinar will include a lively discussion on current postoperative therapies, novel approaches that may improve efficacy and adherence, pivotal clinical trial data, and the importance of personalized treatment plans.  

    This activity is supported by an independent medical education grant from EyePoint Pharmaceuticals.

  • Learning Objectives

    Upon completion of this activity, the participant should be able to:

    • Describe the limitations of postoperative topical corticosteroids
    • Categorize the novel approaches to manage and/or prevent posterior inflammation that may improve efficacy and adherence
    • Interpret pivotal clinical trial data leading to FDA approvals of sustained-release devices for posterior segment inflammation
    • Create personalized treatment plans based on patient needs and preferences
    • Discuss the literature on alternative therapies, including their safety, efficacy, and ideal patient selection

    • Accreditation

      Provided by Evolve Medical Education

      Accreditation Statement
      Evolve Medical Education LLC (Evolve) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

      Credit Designation Statement
      Evolve designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

       

    • Participation Method

      In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.

    • Faculty and Disclosures

      David A. Eichenbaum, MD, FAAO

      David A. Eichenbaum, MD, FAAO

      Collaborative Associate Professor
      Department of Ophthalmology
      University of South Florida Morsani College of Medicine
      Director of Research
      Retina Vitreous Associates of Florida
      Tampa, Florida


      Daniel F. Kiernan, MD, FACS

      Daniel F. Kiernan, MD, FACS

      Vitreoretinal Surgeon

      The Eye Associates
      Sarasota, FL


      DISCLOSURE POLICY
      It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.

      The following faculty/staff members have the following financial relationships with commercial interests:

      David A. Eichenbaum, MD, FAAO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alimera Sciences, Allergan, EyePoint Pharmaceuticals, Genentech, Gyroscope, IvericBio, Kodiak, Notal Vision, Novartis, and Regeneron Pharmaceuticals. Grant/Research Support: Alkahest, AsclepiX, Bayer, Chengdu, Gemini, Genentech, Gyroscope, lonis, lvericBio, Kodiak, Mylan, NGM, Novartis, Opthea, and Regeneron Pharmaceuticals. Speaker’s Bureau: Allergan, Bayer, DORC, EyePoint Pharmaceuticals, Genentech, and Novartis.

      Daniel F. Kiernan, MD, FACS, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, EyePoint Pharmaceuticals, and Physician Recommended Nutraceuticals. Grant/Research Support: EyePoint Pharmaceuticals and Gyroscope. Speaker’s Bureau: Alimera, Allergan, EyePoint Pharmaceuticals, Mallinckrodt, Novartis, Physician Recommended Nutraceuticals, Regeneron Pharmaceuticals, and Spark Therapeutics.

      The Evolve staff and planners have no financial relationships with commercial interests.
      Mark Goerlitz-Jessen, peer reviewer, has no financial relationships with commercial interests.

    • Disclaimer

      OFF-LABEL STATEMENT
      This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

      DISCLAIMER
      The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or EyePoint Pharmaceuticals.

    • System Requirements

      • Supported Browsers (2 most recent versions):
        • Google Chrome for Windows, Mac OS, iOS, and Android
        • Apple Safari for Mac OS and iOS
        • Mozilla Firefox for Windows, Mac OS, iOS, and Android
        • Microsoft Edge for Windows
      • Recommended Internet Speed: 5Mbps+

    • Publication Dates

      Release Date:

      Expiration Date:

    Ready to Claim Your Credits?

    You have attempts to pass this post-test. Take your time and review carefully before submitting.

    Good luck!

    LIVE ON REACHMD RADIOBack to live radio
    ReachMD Radio

    Loading...

    00:00
    00:00
      Register

      We're glad to see you're enjoying Evolve Medical Education…
      but how about a more personalized experience?

      Register for free